参考文献:
1. 王熙龙, 等. 国际呼吸杂志,2023,43(2):150-154.
2. T. Myrberg, et al. PRISm is an independent risk factor for development of COPD. ERS 2024. Poster 1292.
3. Q. Liu, et al. The prevalence, clinical characteristics, and influencing factors of COPD progressed from PRISm: a cohort analysis in primary healthcare organizations in China. ERS 2024. Poster 4326.
4. L. Pinto, et al. Comparing the PUMA and CAPTURE questionnaires for screening for COPD in resource constrained settings. ERS 2024. Poster 2152.
5. K. Huang et al. Impact of using pre- and post-bronchodilator spirometry reference values in a Chinese population. ERS 2024. Poster 3069.
6.B. Zhang, et al. The Value of Deep Learing for COPD Diagnosis and Grading. ERS 2024. Poster 5240.
7. A. Sunjaya, et al. Identification of COPD from primary care spirometry with artificial intelligence (AI) interpretation software: a retrospective, diagnostic accuracy study. ERS 2024. Poster 1047.
8. Paul Jones, et al. Exploration of specific domains within the COPD assessment test (CAT). ERS 2024. Poster 2162.
9. Peter Ascanius Jacobsen, et al. Historical blood eosinophil levels in adults with and without obstructive airways disease. ERS 2024. Poster 440.
10. Kocks J, et al. NPJ Prim Care Respir Med. 2023 May 3;33(1) 18.
11. 门诊慢性阻塞性肺疾病急性加重识别调研协助专家组. 国际呼吸杂志,2024,44(4):397-404.
12. Zhoude Zheng, et al. Factors Associated with Acute Exacerbations in Non-Smoking Patients with COPD in China: Findings from the Enjoying Breathing Program. ERS 2024. Poster 4898.
13. 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 等. 中华结核和呼吸杂志,2022,45(12):1180-1191.
14. 戴中上, 结核与肺部疾病杂志,2023,4(06):499-505.
15. Andriana Papaioannou, et al. A Delphi Consensus Project to Capture Experts’ Opinion on the Position of Triple Therapies in COPD:Why, When and to Whom. ERS 2024. Poster 4791.
16. 慢性阻塞性肺疾病糖皮质激素规范管理撰写组. 中华结核和呼吸杂志, 2021, 44(12) : 1054-1063.
17. GOLD 2011.
18. GOLD 2023.
19. G. Rodrigues, et al. Trends in initial pharmacological treatment of COPD in Dutch primary care: a real-world analysis. ERS 2024. Poster 1302.
20. Palli SR, et al. J Manag Care Spec Pharm. 2021 May;27(5):625-637.
22. Henrik Watz, et al. Characteristics of patients with COPD treated with Budesonide/Glycopyrronium/Formoterol in the real world; The RECORD Study. ERS 2024. Poster 4798.
23. Zhiwei Lin, et al. Exploring the Therapeutic Potential of Isorhamnetin in the Treatment of Chronic Obstructive Pulmonary Disease via the Ferroptosis Pathway: A Network Pharmacology and Experimental Study. ERS 2024. Poster 832.